Criticism mounting over Zuellig Korea's excessive royalty payment to HK-based headquarters

Published: 2004-05-20 07:00:00

Updated: 2004-05-20 07:00:00

With Zuellig Korea's recent announcement that for the past four years it had paid a total of 5.4 billion won to Hong-Kong-based Zuellig Pharma Holding Limited, known as the largest shareholder, in return for market and information service assistance, criticism is mounting over how such large roya...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK